Hypertrophic Cardiomyopathy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hypertrophic Cardiomyopathy – Pipeline Review, H2 2017’, provides an overview of the Hypertrophic Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy

The report reviews pipeline therapeutics for Hypertrophic Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypertrophic Cardiomyopathy therapeutics and enlists all their major and minor projects

The report assesses Hypertrophic Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypertrophic Cardiomyopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

C&C BioPharma LLC

Lead Discovery Center GmbH

MyoKardia Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypertrophic Cardiomyopathy - Overview

Hypertrophic Cardiomyopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hypertrophic Cardiomyopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development

C&C BioPharma LLC

Lead Discovery Center GmbH

MyoKardia Inc

Hypertrophic Cardiomyopathy - Drug Profiles

8-MI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUS-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavacamten - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Cardiac Hypertrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypertrophic Cardiomyopathy - Dormant Projects

Hypertrophic Cardiomyopathy - Discontinued Products

Hypertrophic Cardiomyopathy - Product Development Milestones

Featured News & Press Releases

Sep 18, 2017: MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting

Aug 07, 2017: MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Nov 11, 2016: MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

Nov 02, 2016: MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Sep 21, 2016: MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day

Jul 14, 2016: SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy

Jul 11, 2016: MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

May 02, 2016: MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Feb 04, 2016: MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy

Oct 06, 2015: MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy

Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Hypertrophic Cardiomyopathy – Pipeline by C&C BioPharma LLC, H2 2017

Hypertrophic Cardiomyopathy – Pipeline by Lead Discovery Center GmbH, H2 2017

Hypertrophic Cardiomyopathy – Pipeline by MyoKardia Inc, H2 2017

Hypertrophic Cardiomyopathy – Dormant Projects, H2 2017

Hypertrophic Cardiomyopathy – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports